Keyuan Pharma(301281.SZ)

Company Encyclopedia
View More
name
Keyuan Pharma
301281.SZ
Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clemastine fumarate; chlorpheniramine maleate; esmolol hydrochloride; nicotinamide-tinidazole; amlexanox; nisoldipine; qupibutu; clarithromycin lactobionate; propafenone hydrochloride; potassium diclofenac; chlorzoxazone; esomeprazole sodium; palonosetron hydrochloride; dalafeng; piroxicam; phenylephrine; vildagliptin; parecoxib sodium; ruxolitinib hydrochloride; and lurasidone hydrochloride. The company was incorporated in 2004 and is headquartered in Jinan, China.
3.027 T
301281.SZMarket value -Rank by Market Cap -/-

Financial Score

02/01/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking162/222
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.85%C
    • Profit Margin11.95%B
    • Gross Margin47.76%B
  • Growth ScoreC
    • Revenue YoY-0.52%D
    • Net Profit YoY3.77%C
    • Total Assets YoY9.64%B
    • Net Assets YoY2.54%C
  • Cash ScoreC
    • Cash Flow Margin836.59%B
    • OCF YoY-0.52%D
  • Operating ScoreD
    • Turnover0.28D
  • Debt ScoreA
    • Gearing Ratio14.60%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Keyuan Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 31.4707 million yuan, a decrease of 20.69%

    Keyuan Pharma released its Q3 2025 report, with operating revenue for the first three quarters at 303 million yuan, a year-on-year decrease of 8.52%. The net profit attributable to the parent company was 31.4707 million yuan, a year-on-year decline of 20.69%; the net profit excluding non-recurring gains and losses was 22.6467 million yuan, a year-on-year decrease of 15.84%. The basic earnings per share were 0.2906 yuan

    Zhitong·
    SZ
    301281
    -0.68%
    Zhitong·
    SZ
    301281
    -0.68%

    Keyuan Pharma: Received the "Decision on Not Implementing Further Review of Antitrust Review of Operator Concentration" from the State Administration for Market Regulation

    Keyuan Pharma announced that the company plans to acquire 99.42% equity of Shandong Hongjitang Pharmaceutical Group by issuing shares and raising matching funds. The transaction has received a decision from the State Administration for Market Regulation stating that no further antitrust review will be conducted, but it still needs to be reviewed by the Shenzhen Stock Exchange and registered with the China Securities Regulatory Commission, and there is uncertainty regarding the final success of the transaction

    Zhitong·
    SZ
    301281
    -0.68%
    Zhitong·
    SZ
    301281
    -0.68%

    Keyuan Pharma's application for additional issuance related to acquisition matters has been accepted by the Shenzhen Stock Exchange

    According to the Zhitong Finance APP, Keyuan Pharma announced that on June 27, 2025, it received a notice from the Shenzhen Stock Exchange regarding the acceptance of the application documents for the issuance of shares to purchase assets and raise supporting funds by Shandong Keyuan Pharmaceutical Co., Ltd. The Shenzhen Stock Exchange verified the application documents submitted by the company, deemed them complete, and decided to accept them

    Zhitong·
    SZ
    301281
    -0.68%
    Zhitong·
    SZ
    301281
    -0.68%

    Keyuan Pharma has established a new subsidiary in Guangzhou

    According to the Qichacha APP, recently, Keyuan Pharma Co., Ltd. was established, with Gao Chunpo as the legal representative. The business scope includes: sales of disinfection equipment; operation of Class III medical devices; wholesale of pharmaceuticals; import and export of pharmaceuticals, etc. Qichacha's equity penetration shows that the company is wholly owned by Keyuan Pharma

    Zhitong·
    SZ
    301281
    -0.68%
    Zhitong·
    SZ
    301281
    -0.68%

    Keyuan Pharma fell over 10% as shareholder Wen Zehong plans to reduce holdings by no more than 3% of the company's shares

    Keyuan Pharma is currently down 10.44%, trading at 31.57 yuan, with a transaction volume of 260 million yuan and a latest market value of 3.4 billion yuan. Keyuan Pharma announced that its shareholder Wen Zehong plans to reduce his holdings in the company by no more than 3,248,700 shares through centralized bidding and block trading, accounting for 3% of the company's total share capital. The reduction period is within three months after the fifteenth trading day from the date of the announcement

    Zhitong·
    SZ
    301281
    -0.68%
    Zhitong·
    SZ
    301281
    -0.68%
    © 2026 Longbridge｜Disclaimer